Detailed narrative
Anaphylm Resubmission and Clinical Data
Aquestive is on track to resubmit its Anaphylm NDA to the FDA in Q3 2026, following a complete response letter earlier in the year. The resubmission includes results from a human factors validation study, which showed a significant reduction in packaging difficulty and film tearing after updates. A pharmacokinetic (PK) study demonstrated no statistical difference between clinician-administered and self-administered drug product, and even with purposeful misplacement (top of tongue), rapid and meaningful pharmacodynamic responses were observed, comparable to manual IM epinephrine.
Anaphylm Market Opportunity and Commercial Strategy
The company believes the epinephrine rescue market, estimated at $1 billion to potentially $2 billion annually, presents a compelling opportunity for Anaphylm. The market has grown annually by approximately 6% and is dominated by outdated technology. Aquestive plans an allergist-focused launch strategy to efficiently convert prescriptions, emphasizing Anaphylm's clinical differentiation, ease of use, and portability. Payer coverage is anticipated to be driven by the product's clinical benefits beyond just being a 'no-needle' solution.
AQST-108 Atopic Dermatitis Program
Aquestive is advancing AQST-108 for atopic dermatitis, leveraging a localized topical epinephrine application. Preclinical and human trials have shown TSLP, CCL3, and CCL4 suppression, and NF-KB modulation, which are key in alleviating itch associated with atopic dermatitis. The company believes this approach could offer a meaningful treatment, potentially with less frequent dosing than daily, positioning it against both low-cost generics and higher-priced biologics. Further updates are expected after the Anaphylm resubmission.
Partnering and Base Business Activities
The company is actively pursuing partnering opportunities for Libervant in the U.S. and Anaphylm outside of the U.S. The base business, including Suboxone manufacturing, continues to generate consistent cash flow. Management believes the proposed Indivior-Supernus merger will not have a near-term impact on its base business, given the ongoing importance of Suboxone. The refinancing with Oaktree provides a new $150 million debt facility, lowering capital costs and extending the interest-only period.
Financial Performance and Capital Allocation
Aquestive reported a 38% increase in total revenues for Q2 2026 and a 51% increase for the first six months of 2026, driven by manufacturing and supply, and license and royalty revenues. Non-GAAP adjusted EBITDA loss improved significantly year-over-year. The company ended Q2 with $98.5 million in cash and cash equivalents and expects additional launch funding of $75 million from RTW and $20 million from Oaktree upon Anaphylm FDA approval. Capital allocation remains disciplined, focusing on Anaphylm resubmission, launch preparations, and AQST-108 advancement.